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Screening of BK virus (BKV) replication is recommended to identify patients at increased risk of BKV-associated diseases. How-
ever, the heterogeneity of molecular techniques hinders the establishment of universal guidelines for BKVmonitoring. Here we
aimed to compare the performance of the CE-marked BK virus R-gene kit (R-gene) to the performance of our in-house assay for
quantification of BKVDNA loads (BKVL). A 12-specimen panel from the Quality Control for Molecular Diagnostics (QCMD)
organization, 163 urine samples, and 88 paired specimens of plasma and whole blood (WB) from transplant recipients were
tested. Both the R-gene and in-house assays showed a good correlation within the QCMD panel (r 0.995 and r 0.989, respec-
tively). BKVL were highly correlated between assays, although positive biases were observed with the in-house assay in analysis
of urine (0.72 0.83 log10 copies/ml), plasma (1.17 0.63 log10 copies/ml), andWB (1.28 0.37 log10 copies/ml). Recalibration
with a common calibrator significantly reduced the bias in comparisons between assays. In contrast, BKVL was underestimated
with the in-house PCR in eight samples containing BKV genotype II, presenting point mutations at primer-annealing sites. Us-
ing the R-gene assay, plasma andWB specimens were found to be equally suitable for quantification of BKVL, as indicated by the
high correlation coefficient (r 0.965, P< 0.0001). In conclusion, the R-gene assay demonstrated reliable performance and
higher accuracy than the in-house assay for quantification of BKVL in urine and blood specimens. Screening of BKV replication
by a well-validated commercial kit may enable clinical laboratories to assess viral loads with greater reproducibility and
precision.
The BK virus (BKV)-associated disease most frequently seenafter renal transplantation is BKV-associated nephropathy
(BKVN). BKV reactivation occurs in up to 50% of kidney trans-
plant recipients (KTR)within the first year of transplantation, and
7% to 10% of patients progress to BKVN, resulting in graft dys-
function or loss (1). BKVNhas also been reported in other immu-
nocompromised patients such as lung transplant recipients (2, 3)
and cardiac transplant patients (4, 5). This is a growing medical
problem as the population of transplant recipients continues to
increase. The underlying pathogenic mechanism of BKVN is not
well defined (6). Disruption of the balance between BKV replica-
tion and host immune control is generally viewed as a key element
of viral pathogenesis (7). Thus, to date, the mainstay therapeutic
option for BKVN is a reduction of immunosuppression, which
allows reconstitution of the immune response to clear the virus (8)
but potentially increases the risk of graft rejection.
According to Kidney Disease Improving Global Outcomes
(KDIGO) (9) and the 2014 European guidelines (10), all KTR
should be regularly screened for BKV replication in plasma or
urine to identify patients at increased risk of BKVN. A sustained
BKV viremia level above the threshold of 4 log10 copies/ml has
been defined as indicating “presumptive” BKVN (11), and high-
level BKVviruria usually precedes viremia and potential nephrop-
athy by 4 to 12 weeks. Thus, it is recommended to screen the BKV
DNA load (BKVL) in plasma monthly in the first 6 months post-
transplant, followed by 3-monthly screening until 2 years post-
transplant, in order to guide therapeutic intervention for KTR
patients with probable or proven BKVN. However, most BKV
quantitative PCR methods are in-house techniques, and marked
variability among assays has been described (12). A recent study
demonstrated that, depending on the PCR assay, the currently
recommended BKV viremia cutoff of 4 log10 copies/ml may
underestimate the prevalence of BKVN (13). The variability of the
assays may be attributable to various criteria: features of primers
and probe design, including the size of the amplicon and the
choice of reference material and/or types of matrices used for the
blood compartment (plasma or whole blood [WB]) (12, 14).
Hence, the wide heterogeneity of molecular techniques limits in-
terlaboratory comparison and hinders the establishment of uni-
versal cutoff points of BKVL with high predictive positive values
for the identification of patients at risk for BKVN.Therefore, there
is a need to standardize BKVL determination in order to improve
its reliability and allow unequivocal comparison of different pa-
tient populations.
This study aimed to evaluate the performance of the BK Virus
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R-gene kit (R-gene) (bioMérieux, France) for quantification of
BKVL in urine and blood samples from transplant recipients com-
pared to the performance of our referral in-house assay, with both
techniques targeting the stable genomic region encoding the small
t antigen (StAg). Additionally, we compared the quantitative re-
sults of analyses of paired plasma and WB samples using the R-
gene assay to determine if both matrices could provide appropri-
ate biological material for BKVL quantification. Finally, we
evaluated the relative diagnostic values of BKVL in plasma and
WB samples longitudinally collected from 3 KTR.
MATERIALS AND METHODS
Specimen collection. A total of 163 urine specimens from 134 patients
and 88 paired aliquots of plasma and WB samples from 39 patients sub-
mitted to our clinical laboratory for BKV testing were prospectively col-
lected and stored at 80°C. Urine and blood samples were collected si-
multaneously for 15 patients. The study population comprised 146 KTR,
6 lung transplant recipients, and 6 hematopoietic stem cell transplant
patients. Among the KTR, 7 patients had developed BKVN, 6 of the 7
within 4 months after kidney transplant. BKVN was confirmed histolog-
ically on kidney biopsy specimens. For 3 KTR patients, plasma and WB
samples were longitudinally collected in order to compare BKVL dynam-
ics in the twoblood compartments. Twelve samples of theQualityControl
Molecular Diagnostics (QCMD) 2012 BKV proficiency panel were tested
by the two assays. This study was approved by the Institution Review
Board of Strasbourg University Hospital.
BKVDNA load quantification.Viral DNAwas extracted from 200l
of urine, plasma, or WB samples. An internal inhibition control was
added to the lysis buffer and simultaneously purifiedwith viralDNAusing
specific protocol B on the NucliSENS easyMAG system (bioMérieux,
France). Urine and blood samples were eluted in 100 l and 50 l of
elution buffer, respectively. Ten microliters of purified DNA was pro-
cessed by the in-house quantitative real-time PCR assay using a Light-
Cycler 2.0 instrument (Roche Diagnostics, Basel, Switzerland) as de-
scribed previously (15). The R-gene PCR was performed in a 25-l
volume containing 15 l of the amplification premix and 10 l of stan-
dard or sample DNA using a LightCycler 480 II instrument (Roche Diag-
nostics, Basel, Switzerland). The twomethods amplify a conserved region
in the small t antigen (StAg) gene but target different sites. The dynamic
quantification ranges are 2.40 to 11.40 log10 copies/ml for the in-house
PCR assay and 2.70 to 11.00 log10 copies/ml for the R-gene assay.
Sequencing of VP1 and small t antigen regions. Amplification of the
StAg gene was performed by nested PCR on 5 l of eluted DNA, with
outer primers BK2Reverse (5=-CAAAGAAGGACCCCAATGCC-3= [po-
sitions 1075 to 1094, Dunlop sequence]) and BK9Forward (5=-TACATA
CCTAATAATAAAAACACATCCTCACACT-3= [3929 to 3962]) and in-
ner primers BK1Reverse (5=-GAACCATGGCCTTTGTCCAG-3= [375 to
394]) and BK5Forward (5=-TACACAGCAAAGCAGGCAAG-3= [4319 to
4338]). Amplification products were sequenced with the BK1Reverse and
BK5Forward primers, and sequencing results were aligned using Gentle
software (University of Cologne, Cologne, Germany). Amplification of
the BKV capsid protein viral protein 1 (VP1) gene was performed by PCR
on 5l of elutedDNA, using a primer set consisting of upstream sequence
BK3F (5=-CCCCAGGAGGTGCTAATCAA-3= [positions 1465 to 1484])
and downstream sequence BK3R (5=-CCCTGCATTTCCAAGGGTTC-3=
[2035 to 2054]). The VP1 gene “typing region” was sequenced using
primer set F1n (5=-CTTGAAGCATATGAAGATGGC-3=) and R1n (5=G
ACCCTGCATGAAGGTTAAGC-3=), as described previously (16). BKV
genotypes were determined using BLAST alignment software.
Statistical analysis. Statistical analysis was performed using Graph-
Pad Prism6 software and GraphPad StatMate 2.0 software (GraphPad;
San Diego, CA). Agreement of results and correlations between R-gene
and in-house assays were assessed with Bland-Altman analyses and Dem-
ing regression analyses. Correlations between BKVL levels measured in
plasma andWB samples were determined by a Spearman correlation test.
Power analysis was performed to detect a difference of 0.45 log10 between
means with a significance level (alpha) of 0.05 (two-tailed test).
RESULTS
Analytical precision and sensitivity and specificity of theR-gene
quantification kit.TwoBKV-positive samples of theQCMD2009
proficiency panel were chosen to perform intra- and interassay
precision analyses through two serial dilutions in negative plasma
10 times. The coefficient of variation ranged from 0.83% to 3.99%
for intra-assay precision and from 1.76% to 3.61% for interassay
precision (Table 1). For determinations of limits of detection
(LOD), the contents of an AcroMetrix BKV panel (Life Technol-
ogies, France) were diluted in plasma, urine, orWB. Each dilution
was extracted and then amplified 15 times. The 95% LOD were
2.44 log10 copies/ml, 2.30 log10 copies/ml, and 2.48 log10 copies/ml
in urine, plasma, andWB samples, respectively. No cross-reaction
was observed with JC virus (ATCC reference VR-21583), adeno-
viruses (VR-3), or the following human herpesviruses: herpes
simplex virus 1 (HSV1; VR-260), HSV2 (VR540), varicella zoster
virus (VZV; VR-916), human herpesvirus 6 (HHV-6; VR1480),
cytomegalovirus (CMV; VR-977), and Epstein-Barr virus (EBV;
Raji cells).
Results from theQCMD2012BKVproficiency panel.Twelve
samples from the QCMD 2012 BKV proficiency panel were tested
with the in-house and the R-gene assays. Results are depicted in
Table 2. The two assays were highly concordant, as the 7 samples
for which a negative result was expected were found to be negative
and 5 samples were found to be positive. A perfect correlation for
the assays in comparison to the QCMD expected values (in-house
r 0.989; R-gene r 0.995) was obtained. For quantitative anal-
ysis, our results were compared to the consensus mean and stan-
dard deviation calculated from all the data returned by the partic-
ipants to the QCMD 2012 BKV proficiency panel. The values of
the positive results obtained with the in-house assay were slightly
higher than those of the QCMD expected results, with a mean
difference of 0.71 0.31 log10 copies/ml. Meanwhile, the R-gene
PCR results were close to theQCMDexpected values, with amean
difference of 0.17 0.15 log10 copies/ml.
High concordance of qualitative results between R-gene and
in-house PCR assays. Qualitative analysis revealed a 98.8% con-
cordance level between assays in urine, a 98.9% concordance level
in plasma, and a 95.5% concordance level in WB specimens. To-
tals of 155 urine, 87 plasma, and 84 WB samples were positively
detected by both PCR techniques. One urine specimen and one
WB specimen were weakly positive with the in-house PCR assay
and negative with the R-gene kit, while 1 urine sample and 4 blood
samples were identified as positive with the R-gene assay only.
TABLE 1 Inter- and intra-assay precision of the R-gene assaya
Parameter and precision
level (log10 copies/ml)
Mean SD
(log10 copies/ml) CV (%)
Intra-assay
4.2 4.63 0.04 0.83
3.2 3.50 0.14 3.99
Interassay
4.0 4.06 0.07 1.76
3.0 2.89 0.10 3.61
a Abbreviations: SD, standard deviation; CV, coefficient of variation.
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Correlation of quantitative results between R-gene and in-
house PCR assays.Overall, the samples testedwere representative
of the entire dynamic range. As shown in Fig. 1A, B, and C, BKVL
levels were highly correlated between assays for urine and blood
specimens. The slopes of the Deming regression lines were 1.05
(95% confidence interval [CI], 0.99 to 1.11), 0.84 (95%CI, 0.68 to
0.99), and 1.12 (95% CI, 1.01 to 1.23) for the urine, plasma, and
WB specimens, respectively. Bland-Altman analysis showed a bias
of 0.72 0.83 log10 copies/ml (mean difference standard devi-
ation) for urine samples (Fig. 1D). Values of mean differences
between the two assays were slightly higher for plasma and WB
samples, with biases of 1.17  0.63 log10 copies/ml and 1.28 
0.37 log10 copies/ml, respectively (Fig. 1E and F). These data sug-
gest that BKVL are overestimated by the in-house PCR compared
to the R-gene assay. This could result from the use of different
standard materials in the two techniques to generate the calibra-
TABLE 2 Results from the QCMD 2012 BKV proficiency programa
Sample no.
QCMD 2012 result or
consensus log10 virus
concn R-gene assay result In-house PCR result
Mean SD
BKV load
(log10 copies/ml)
Delta log10
(R-gene QCMD)
BKV load
(log10 copies/ml)
Delta log10
(In-house QCMD)
QCMD 2012-01 Negative Negative ND Negative ND
QCMD 2012-02 3.62 0.56 3.62 0.00 4.43 0.81
QCMD 2012-03 2.67 0.47 2.93 0.26 3.57 0.90
QCMD 2012-04 Negative Negative ND Negative ND
QCMD 2012-05 Negative Negative ND Negative ND
QCMD 2012-06 Negative Negative ND Negative ND
QCMD 2012-07 1.95 0.57 (2.13) 0.18 (2.11) 0.16
QCMD 2012-08 4.71 0.56 4.77 0.06 5.47 0.76
QCMD 2012-09 Negative Negative ND Negative ND
QCMD 2012-10 Negative Negative ND Negative ND
QCMD 2012-11 Negative Negative ND Negative ND
QCMD 2012-12 5.28 0.49 5.66 0.38 6.20 0.92
a Consensus log10 virus concentrations were calculated as the mean values reported from 181 datasets submitted by clinical laboratories. Abbreviations: SD, standard deviation; ND,
not determined; delta log10, log10 copies/ml difference between the R-gene and the in-house PCR assays in the QCMD panel. Values in parentheses are below the limit of
quantification for both tests.
FIG 1 Deming regression and Bland-Altman analysis for the BK virus R-gene and the in-house assays. (A to C) The Deming regression curve equation and 95%
confidence interval (CI 95%) of the slope are indicated for urine (A), plasma (B), and whole-blood (C) specimens. (D to F) Bland-Altman plots of urine (D),
plasma (E), and whole-blood (F) specimens are shown. Solid lines represent the means of the differences between the results of the two assays; dashed lines
indicate the limits of agreement between the two methods (1.96 the standard deviation). BKV, BK virus.
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tion curves. To test this hypothesis, the two assays were recali-
brated to a common calibrator, theAcroMetrix BKVpanel, and 25
randomly selected blood samples were retested. As shown in Fig.
2, the use of a common calibrator significantly reduced the bias
between assays from 1.09 to 0.69 log10 (P 0.0001), demonstrat-
ing that using different standard materials impacts the agreement
between assays.
Analysis of discrepant samples. While BKVL values were on
average higher with the in-house assay, 5/163 urine and 3/88
blood samples showed lower viral loads with the in-house PCR
assay than with the R-gene assay (mean difference, 2.95 log10
copies/ml). Because of the low DNA viral loads, the StAg gene
could be amplified by PCR in only 4 samples. Sequence analysis of
the StAg gene revealed one and two mismatches at the 3= position
of the forward and reverse primers, respectively, and an additional
mutation at the 5= position of the probe of the in-house PCR.
Thesemismatches are likely to hinder annealing and amplification
of the primers. Further sequencing of the VP1 gene typing region
showed the presence of BKV genotype II in all discrepant samples.
The same mutations observed in the discrepant samples can be
found in several genotype II reference strains (GenBank accession
no. AB263916 [ETH3] and AB263920 [GBR-12]). As a result of
excluding these discordant samples, Deming regression slopes
were 1.06 (95% CI, 1.04 to 1.08), 1.09 (95% CI, 0.98 to 1.19), and
1.12 (95% CI, 1.01 to 1.23) and biases were 0.85  0.32 log10
copies/ml, 1.25  0.33 log10 copies/ml, and 1.28  0.37 log10
copies/ml for urine, plasma, and WB specimens, respectively.
Both plasma and WB matrices are appropriate for BKVL
measurement. Although European guidelines recommend mon-
itoring BKVL in plasma, numerous diagnostic laboratories quan-
tify BKVL in WB (personal communication). In order to deter-
mine if plasma and WB would provide equivalent materials,
BKVL levels were compared in 88 paired aliquots of plasma and
WB. Eighty-seven of 88 samples were positive in both plasma and
WB specimens with the R-gene quantification assay. One sample
was positive in plasma only, with a very low viral load of 2.59 log10
copies/ml. BKVL levels were highly correlated between plasma
andwhole blood, as shown by the correlation coefficient r 0.965
(P  0.0001; 95% CI, 0.947 to 0.977) (Fig. 3A) and a low bias of
0.40 0.23 (Fig. 3B). Given that technical variability of0.5 log10
copies/ml is considered acceptable (17, 18) and of low clinical
relevance (19), our data suggest that both plasma and WB speci-
mens are appropriate for BKVL determination. The statistical
power of this analysis reached 90%.
Furthermore, to compare the BKVLdynamics in the two blood
compartments, BKVL was measured in plasma and WB samples
that were longitudinally collected from 3 KTR. As shown in Fig.
4A and B, patients A and B showed a first positive BK viremia
result at day 119 and day 163 posttransplant, respectively, previ-
ous blood samples having been negative. Of note, their viruria had
been tested positive in our laboratory at day 92 and day 59 post-
transplant, respectively. The first BKVLmeasurement in urine for
patient C occurred 36 days posttransplant and was highly positive
(7.6 log10 copies/ml). BKVL were consequently investigated in
blood samples, and a positive viremia result was found as soon as
day 54 posttransplant (Fig. 4C). This patient developed a BKVN
72 days after transplant, which first prompted a reduction of im-
munosuppression and then further required a switch frommyco-
phenolatemofetil treatment to leflunomide treatment. For these 3
FIG 2 Recalibration of the R-gene and the in-house assays with a common
calibrator. Bland-Altman plots of 25 randomly selected blood samples show-
ing the agreement between assays are represented. BKV loads measured with
assay-specific standard materials (filled circles) and after recalibration with a
common material (AcroMetrix BKV Panel) (open triangles) are shown. The
mean bias was significantly lowered from 1.09 log10 copies/ml (solid line) to
0.69 log10 copies/ml (dashed line) (P 0.0001). BKV, BK virus.
FIG 3 Comparison of BKV loads in plasma and whole-blood specimens with
the R-gene kit. Results of correlation analysis (A) and Bland-Altman analysis
(B) of plasma andwhole-blood BKV loads performedwith the BKVR-gene kit
are shown. Correlation coefficients (r) and 95% confidence intervals (CI 95%)
are indicated. Solid lines represent the means of the differences between the
results determined with the two assays; dashed lines indicate the limits of
agreement between the twomatrices (1.96 the standard deviation). BKV, BK
virus.
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patients, BKVL values were highly correlated between plasma and
WBspecimens. Taken together, these data suggest that plasma and
WB are equally suitable for BKVL monitoring in the blood com-
partment. The StAg gene was sequenced at days 163 and 198 for
patient A, days 133 and 161 for patient B, and days 54, 79, 90, 114,
135, and 177 for patient C. No variability between the StAg gene
sequences could be observed over time for the three patients.
DISCUSSION
The wide variety of in-house quantitative real-time PCR assays
and the lack of international standards result in an important
interlaboratory disagreement with respect to BKVL measure-
ments (12) and thus far have hindered the establishment of a
universal BKVL cutoff value with a high positive predictive value
for presumptive BKVN (13, 14). Commercially available quanti-
tative PCR kits are believed to providemore repeatable and repro-
ducible results, consequently contributing to the efforts of clinical
laboratories regarding the currently ongoing accreditation pro-
cess. This study aimed to compare the performance of a commer-
cially CE-marked assay, the R-gene kit, to the performance of our
referral in-house method, with both techniques targeting the sta-
ble genomic region encoding the StAg.
Regarding the qualitative results, a high level of concordance
between the two PCRmethods was obtained for urine and plasma
as well as forWB specimens. As for the quantitative results, a high
correlation was observed between assays, although BKVL values
appeared to be systematically overestimated by the in-house tech-
nique for each matrix, with blood results displaying the highest
bias. This findingwas further corroborated by the results obtained
with QCMD samples, as the R-gene kit provided values much
closer to the reference data (delta log, 0.17 0.15 log10 copies/ml)
than our in-house technique. This overestimation arises partly
from the different reference materials used for quantification. In-
deed, recalibration of the two assays to a common material re-
sulted in a statistically significant reduction of the bias. The over-
estimation by our in-house technique may result in viral loads
readily overstepping the threshold of 4 log10 copies/ml for pre-
sumptive BKVN and possibly leading to therapeutic intervention
(20, 21). These data highlight the significance of the choice of
reference material and the need for the development of an inter-
national standard.
Features of primer and probe design have also been described
as among the most significant sources of BKVL discrepancies in
comparisons of individual specimens (12). The main BKV
genomic regions depicted as showing sequence divergence are
those encoding theVP1 capsid protein and the large T antigen (22,
23), while the StAg gene is described as displaying only a few single
nucleotide polymorphisms (24). However, despite our assump-
tion that choosing the StAg gene as a PCR target for our in-house
PCR would provide a less variable technique for quantification,
discrepant BKVL results were observed for some individuals
due to mutations at positions G4830A, A4836T, G4876A, and
G4877A. These mutations were located2 bp from the 3= end of
the forward and reverse primers, thus explaining their impact on
BKVL quantification (25). Sequence alignment using published
BKV strains demonstrated that these mutations were specific to
BKV genotype II (26). BKV genotyping performed by sequencing
the VP1 gene typing region confirmed that all discrepant samples
contained this rare BKV genotype. Nevertheless, the R-gene kit,
although targeting the same gene, allowed correct quantification
of these samples. It has to be noted that primers and probes of the
R-gene kit were designed to allow the amplification of BKV strains
from the four existing genotypes, while those of our in-house PCR
target the Dunlop reference strain belonging to genotype I. These
data indicate that PCR assays based on primers and probes de-
signed solely for one BKV genotype may underestimate BKVL.
Thus, if clinical assumption of the presence of BKVN is strong,
albeit not corroborated by a high viral load, wewould recommend
performing BKVL quantification by another laboratory using an
assay validated for all BKV genotypes. We would also suggest se-
quencing the VP1 gene typing region and the PCR target gene
FIG 4 Follow-up of BKV loads in three kidney-transplant patients. BKV loads
in plasma (solid lines) and whole-blood (dashed lines) specimens longitudi-
nally collected from three kidney recipientsweremeasured and compared. The
StAg gene was sequenced for the samples indicated with an asterisk. BKV, BK
virus; BKVN, BK virus-associated nephropathy; IS, immunosuppressive
drugs.
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when possible in order to detect uncommon genotypes and point
mutations potentially impeding PCR amplification.
The KDIGO and European guidelines recommend close
screening of BKV in plasma and urine during the first months
after kidney transplantation. Monitoring of BKV viruria is
noninvasive and can be informative, as a high level of BK viru-
ria usually precedes viremia and potential nephropathy by 4 to
12 weeks (1, 27). Even though a cutoff value or a positive pre-
dictive value is hard to define, a viruria level of7 log10 should
alert clinicians and indicate the need to increase surveillance of
viremia (28). Regarding the assessment of BKVL in the blood
compartment, validation of WB as an appropriate matrix was
recently carried out (29), but no study thus far has endeavored
to contrast plasma and WB samples for BKVL determination.
Comparison between serum and plasma samples has been per-
formed and revealed a significantly lower level of BKVL in
serum than in plasma, demonstrating in that circumstance the
importance of choosing one specific type of sample for moni-
toring viral load over time (30). In our study, BKVL values were
highly correlated in plasma and WB and the follow-up of three
patients showed similar kinetics of BKVL in the two types of
samples. Both matrices could thus be used for BKVL determi-
nations in the blood compartment. Nevertheless, WB is the
preferred clinical sample for detection of other opportunistic
viruses such as cytomegalovirus (CMV) and Epstein-Barr virus
(EBV) (31, 32) in transplant recipients. Using the same type of
sample for all viruses could be more convenient for the moni-
toring of these patients, as the extraction would need to be
performed only once for the entire viral screening panel, with
significant time and cost saving. Furthermore, WB samples do
not necessitate centrifugation or other manipulations that
would increase the risk of sample carry-over. Only a small vol-
ume of WB is required for DNA extraction, and long-term
storage can be achieved by simple guanidine thiocyanate lysis.
In this study, few KTR developed BKVN and only one was
longitudinally followed up; hence, we were not able to define a
clinical threshold of viremia for presumptive BKVN.
It has to be noted that our findings apply only to the R-gene
assay and our in-house assay. Other laboratories that use different
extraction platforms and/or different laboratory-developed tests
(targeting a different gene) may show differing results. Whether
the use of the R-gene assay factually reduces the interlaboratory
variability is also to be investigated. A multisite study comparing
the performances of different laboratories using various BKV
quantitative PCRs to detect BKV in the same panel of samples is
warranted.
In conclusion, the R-gene assay demonstrated reliable perfor-
mance and higher accuracy than the in-house assay for quantifi-
cation of BKVL in urine and blood specimens. Using a commer-
cial kit may enable clinical laboratories to assess viral load with
greater reproducibility and precision. Indeed, standards, reagents,
and internal controls made according to good manufacturing
practices are already provided and their use requires fewermanip-
ulations and adjustments. Nevertheless, it is crucial to pursue ef-
forts to develop international standards and reference material in
order to improve the standardization of BKV quantitative PCR
and eventually define consensus threshold values for therapeutic
intervention.
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